Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease

Tomislav Jukic; David Drobne; Sasa Pusavec; Alojz Ihan; David Stubljar; Andrej Starc

doi:10.12659/MSM.939084

18 February 2023: Clinical Research

Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease

Tomislav Jukic ^1CDEF , David Drobne ^2ABCDE , Sasa Pusavec ^3BF , Alojz Ihan ^3AE , David Stubljar ^4ACDE* , Andrej Starc ^5DE

DOI: 10.12659/MSM.939084

Med Sci Monit 2023; 29:e939084

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 1 Linear regression graph of IFX concentrations. (A) comparison of apDia and Lisa Tracker; (B) comparison of University of Leuven (UHL) UHL and apDia; (C) comparison of UHL and Lisa Tracker. (Microsoft Excel, version 2208, Microsoft).

Back to the Article

Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease

Your Privacy